> top > docs > PubMed:23704994 > annotations

PubMed:23704994 JSONTXT

Annnotations TAB JSON ListView MergeView

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-111 Sentence denotes Eplerenone attenuates pulse wave reflection in chronic kidney disease stage 3-4--a randomized controlled study.
T2 112-123 Sentence denotes BACKGROUND:
T3 124-261 Sentence denotes Patients with chronic kidney disease (CKD) have high cardiovascular mortality and morbidity associated with increased arterial stiffness.
T4 262-388 Sentence denotes Plasma aldosterone levels are increased in CKD, and aldosterone has been found to increase vascular inflammation and fibrosis.
T5 389-511 Sentence denotes It was hypothesized that aldosterone receptor inhibition with eplerenone could reduce arterial stiffness in CKD stage 3-4.
T6 512-525 Sentence denotes STUDY DESIGN:
T7 526-574 Sentence denotes The design was randomized, open, parallel group.
T8 575-652 Sentence denotes Measurements of arterial stiffness markers were undertaken at weeks 1 and 24.
T9 653-666 Sentence denotes INTERVENTION:
T10 667-744 Sentence denotes 24 weeks of add-on treatment with 25-50 mg eplerenone or standard medication.
T11 745-754 Sentence denotes OUTCOMES:
T12 755-829 Sentence denotes Primary outcome parameter was carotid-femoral pulse wave velocity (cfPWV).
T13 830-953 Sentence denotes Secondary outcomes were augmentation index (AIx), ambulatory arterial stiffness index (AASI) and urinary albumin excretion.
T14 954-962 Sentence denotes RESULTS:
T15 963-1042 Sentence denotes Fifty-four CKD patients (mean eGFR 36 mL/min/1.73 m(2), SD 11) were randomized.
T16 1043-1082 Sentence denotes Forty-six patients completed the trial.
T17 1083-1175 Sentence denotes The mean difference in cfPWV changes between groups was 0.1 m/s (95%CI: -1.0, 1.3), P = 0.8.
T18 1176-1256 Sentence denotes The mean difference in AIx changes between groups was 4.4% (0.1, 8.6), P = 0.04.
T19 1257-1291 Sentence denotes AASI was unchanged in both groups.
T20 1292-1421 Sentence denotes The ratio of change in urinary albumin excretion in the eplerenone group compared to the control was 0.61 (0.37, 1.01), P = 0.05.
T21 1422-1568 Sentence denotes Four patients were withdrawn from the eplerenone group including three because of possible side effects; one was withdrawn from the control group.
T22 1569-1638 Sentence denotes Mild hyperkalemia was seen on three occasions and was easily managed.
T23 1639-1651 Sentence denotes LIMITATIONS:
T24 1652-1705 Sentence denotes The full planned number of patients was not attained.
T25 1706-1808 Sentence denotes The duration of the trial may have been too short to obtain full effect of eplerenone on the arteries.
T26 1809-1821 Sentence denotes CONCLUSIONS:
T27 1822-1907 Sentence denotes Add-on treatment with eplerenone in CKD stage 3-4 did not significantly reduce cfPWV.
T28 1908-1993 Sentence denotes There may be beneficial vascular effects leading to attenuated pulse wave reflection.
T29 1994-2023 Sentence denotes Treatment was well-tolerated.
T30 2024-2043 Sentence denotes TRIAL REGISTRATION:
T31 2044-2074 Sentence denotes ClinicalTrials.govNCT01100203.
T1 0-111 Sentence denotes Eplerenone attenuates pulse wave reflection in chronic kidney disease stage 3-4--a randomized controlled study.
T2 112-123 Sentence denotes BACKGROUND:
T3 124-261 Sentence denotes Patients with chronic kidney disease (CKD) have high cardiovascular mortality and morbidity associated with increased arterial stiffness.
T4 262-388 Sentence denotes Plasma aldosterone levels are increased in CKD, and aldosterone has been found to increase vascular inflammation and fibrosis.
T5 389-511 Sentence denotes It was hypothesized that aldosterone receptor inhibition with eplerenone could reduce arterial stiffness in CKD stage 3-4.
T6 512-525 Sentence denotes STUDY DESIGN:
T7 526-574 Sentence denotes The design was randomized, open, parallel group.
T8 575-652 Sentence denotes Measurements of arterial stiffness markers were undertaken at weeks 1 and 24.
T9 653-666 Sentence denotes INTERVENTION:
T10 667-744 Sentence denotes 24 weeks of add-on treatment with 25-50 mg eplerenone or standard medication.
T11 745-754 Sentence denotes OUTCOMES:
T12 755-829 Sentence denotes Primary outcome parameter was carotid-femoral pulse wave velocity (cfPWV).
T13 830-953 Sentence denotes Secondary outcomes were augmentation index (AIx), ambulatory arterial stiffness index (AASI) and urinary albumin excretion.
T14 954-962 Sentence denotes RESULTS:
T15 963-1042 Sentence denotes Fifty-four CKD patients (mean eGFR 36 mL/min/1.73 m(2), SD 11) were randomized.
T16 1043-1082 Sentence denotes Forty-six patients completed the trial.
T17 1083-1175 Sentence denotes The mean difference in cfPWV changes between groups was 0.1 m/s (95%CI: -1.0, 1.3), P = 0.8.
T18 1176-1256 Sentence denotes The mean difference in AIx changes between groups was 4.4% (0.1, 8.6), P = 0.04.
T19 1257-1291 Sentence denotes AASI was unchanged in both groups.
T20 1292-1421 Sentence denotes The ratio of change in urinary albumin excretion in the eplerenone group compared to the control was 0.61 (0.37, 1.01), P = 0.05.
T21 1422-1568 Sentence denotes Four patients were withdrawn from the eplerenone group including three because of possible side effects; one was withdrawn from the control group.
T22 1569-1638 Sentence denotes Mild hyperkalemia was seen on three occasions and was easily managed.
T23 1639-1651 Sentence denotes LIMITATIONS:
T24 1652-1705 Sentence denotes The full planned number of patients was not attained.
T25 1706-1808 Sentence denotes The duration of the trial may have been too short to obtain full effect of eplerenone on the arteries.
T26 1809-1821 Sentence denotes CONCLUSIONS:
T27 1822-1907 Sentence denotes Add-on treatment with eplerenone in CKD stage 3-4 did not significantly reduce cfPWV.
T28 1908-1993 Sentence denotes There may be beneficial vascular effects leading to attenuated pulse wave reflection.
T29 1994-2023 Sentence denotes Treatment was well-tolerated.
T30 2024-2043 Sentence denotes TRIAL REGISTRATION:
T31 2044-2074 Sentence denotes ClinicalTrials.govNCT01100203.

Allie

Id Subject Object Predicate Lexical cue
SS1_23704994_2_0 138-160 expanded denotes chronic kidney disease
SS2_23704994_2_0 162-165 abbr denotes CKD
SS1_23704994_11_0 785-820 expanded denotes carotid-femoral pulse wave velocity
SS2_23704994_11_0 822-827 abbr denotes cfPWV
SS1_23704994_12_0 854-872 expanded denotes augmentation index
SS2_23704994_12_0 874-877 abbr denotes AIx
SS1_23704994_12_1 880-915 expanded denotes ambulatory arterial stiffness index
SS2_23704994_12_1 917-921 abbr denotes AASI
AE1_23704994_2_0 SS1_23704994_2_0 SS2_23704994_2_0 abbreviatedTo chronic kidney disease,CKD
AE1_23704994_11_0 SS1_23704994_11_0 SS2_23704994_11_0 abbreviatedTo carotid-femoral pulse wave velocity,cfPWV
AE1_23704994_12_0 SS1_23704994_12_0 SS2_23704994_12_0 abbreviatedTo augmentation index,AIx
AE1_23704994_12_1 SS1_23704994_12_1 SS2_23704994_12_1 abbreviatedTo ambulatory arterial stiffness index,AASI

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 138-160 HP_0012622 denotes chronic kidney disease

yangbin123xm_800_3

Id Subject Object Predicate Lexical cue
T1 47-69 DP denotes chronic kidney disease
T2 138-160 DP denotes chronic kidney disease
T3 162-165 DP denotes CKD
T4 305-308 DP denotes CKD
T5 497-500 DP denotes CKD
T6 974-977 DP denotes CKD
T7 1858-1861 DP denotes CKD
T8 0-10 CI denotes Eplerenone
T9 710-720 CI denotes eplerenone
T10 451-461 CI denotes eplerenone
T11 1348-1358 CI denotes eplerenone
T12 1460-1470 CI denotes eplerenone
T13 1781-1791 CI denotes eplerenone
T14 1844-1854 CI denotes eplerenone

chenxin_473849_800_3

Id Subject Object Predicate Lexical cue
T1 1844-1854 CI denotes eplerenone
T2 451-461 CI denotes eplerenone
T3 710-720 CI denotes eplerenone
T4 1348-1358 CI denotes eplerenone
T5 1460-1470 CI denotes eplerenone
T6 1781-1791 CI denotes eplerenone
T7 0-10 CI denotes Eplerenone
T8 138-160 DP denotes chronic kidney disease
T9 47-69 DP denotes chronic kidney disease
T10 162-165 DP denotes CKD
T11 305-308 DP denotes CKD
T12 497-500 DP denotes CKD
T13 974-977 DP denotes CKD
T14 1858-1861 DP denotes CKD